Physician profile
Hirendra Doshi
NPI 1356312664
$11,231.55
in general payments reported to CMS, 2019-2025
36 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $999 · 2021: $1,948 · 2022: $2,058 · 2023: $1,719 · 2024: $1,884 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,819.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,444.68 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Pfizer INC. | $1,480.62 | 2019-2025 | |
| Gilead Sciences, INC. | $1,134.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,094.69 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,092.62 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $449.45 | 2019-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $367.78 | 2019-2024 | Dificid |
| Celgene Corporation | $356.46 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $252.53 | 2022-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $237.38 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $219.55 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $200.98 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $190.50 | 2019-2023 | Sutab, Suflave |
| Ardelyx, INC. | $190.00 | 2022-2025 | Ibsrela |
| Amgen INC. | $188.72 | 2020-2023 | Amjevita, Avsola |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $168.44 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $137.98 | 2024-2025 | Voquezna |
| Ucb, INC. | $130.48 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $113.01 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $112.65 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $102.06 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $100.32 | 2019 | |
| Madrigal Pharmaceuticals | $70.37 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $64.94 | 2023 | Idacio |
| Genzyme Corporation | $51.99 | 2025 | |
| Organon LLC | $49.19 | 2021-2023 | Hadlima, Renflexis |
| Janssen Pharmaceuticals, INC | $47.41 | 2019 | |
| Intra-Sana Laboratories | $38.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2021 | |
| Mirum Pharmaceuticals, INC. | $24.29 | 2025 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.46 | 2024 | Cyltezo |
| Medtronic, INC. | $19.21 | 2023 | Gi Genius |
| Dova Pharmaceuticals | $16.89 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.53 | 2020 | |
| Evoke Pharma, INC. | $11.88 | 2021 | |
| Allergan, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hirendra Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.